GLP1R and atherosclerosis: In post hoc analyses of two phase 3 trials testing the GLP-1 receptor agonist semaglutide, randomization to treatment vs. placebo led to significant reductions in proteomic signatures associated with MACE risk.56 in the absence of scalable non-imaging-based endpoints for atherosclerosis, proteomic signatures may offer a promising surrogate endpoint for early-phase trials.